Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Memorial Sloan Kettering Cancer Center · Chinese University of Hong Kong · +44 more institutions
Abstract
fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.
fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety.
Citation impact
- FWCI
- 67.02
- Percentile
- 100%
- References
- 22
Authors
45- ADAlexander DrilonCorresponding
Memorial Sloan Kettering Cancer Center, Chinese University of Hong Kong, Cornell University
- GRGeoffrey R. Oxnard
Memorial Sloan Kettering Cancer Center, Chinese University of Hong Kong, Cornell University, Dana-Farber Cancer Institute
- DSDaniel Shao-Weng Tan
Memorial Sloan Kettering Cancer Center, Chinese University of Hong Kong, Cornell University, National Cancer Centre Singapore
- HHHerbert H. Loong
Memorial Sloan Kettering Cancer Center, Chinese University of Hong Kong, Cornell University
- MLMelissa L. Johnson
Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute, Chinese University of Hong Kong, Cornell University, Sarah Cannon
Topics & keywords
- Medicine
- Internal medicine
- Lung cancer
- Confidence interval
- Chemotherapy
- Adverse effect
- Oncology
- Gastroenterology
- Good health and well-being